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Reducing racial/ethnic disparities in human immunodeficiency virus (HIV) disease is a high priority. Reductions in
HIV racial/ethnic disparities can potentially be achieved by intervening on important intermediate factors. The potential
population impact of intervening on intermediates can be evaluated using observational data when certain conditions
are met. However, using standard stratification-based approaches commonly employed in the observational HIV litera-
ture to estimate the potential population impact in this settingmay yield results that do not accurately estimate quantities
of interest. Here we describe a useful conceptual and methodological framework for using observational data to appro-
priately evaluate the impact on HIV racial/ethnic disparities of interventions. This framework reframes relevant scientific
questions in terms of a controlled direct effect and estimates a corresponding proportion eliminated.We reviewmethods
and conditions sufficient for accurate estimation within the proposed framework.We use the framework to analyze data
on 2,329 participants in the CFAR [Centers for AIDSResearch] Network of Integrated Clinical Systems (2008–2014) to
evaluate the potential impact of universal prescription of and≥95% adherence to antiretroviral therapy on racial dis-
parities in HIV virological suppression.We encourage the use of the described framework to appropriately evaluate
the potential impact of targeted interventions in addressing HIV racial/ethnic disparities using observational data.
health status disparities; HIV
Abbreviations: AA, African-American; ART, antiretroviral therapy; CDE, controlled direct effect; CI, confidence interval; CNICS,
CFAR Network of Integrated Clinical Systems; HIV, human immunodeficiency virus; PE, proportion eliminated; PROs, patient
reported data or outcomes; SD, standard deviation; TE, total effect.
In the United States, African Americans (AAs) are the
racial/ethnic group most affected by the human immunodefi-
ciency virus (HIV) epidemic, disproportionately experiencing
adverse HIV-related outcomes (1–7). Reducing such health dis-
parities is a key component of the USNational HIV/AIDS Strat-
egy (8–10). Racial/ethnic disparities in HIV can potentially be
reduced by intervening on important intermediate factors that
contribute to the disparity. The potential population impact of
intervening on intermediates can be validly evaluated using
observational data when certain conditions are met. However,
using standard stratification-based approaches commonly em-
ployed in the observational HIV literature to estimate the
potential population impact may yield results that do not accu-
rately estimate quantities of interest.
Suppose a researcher has hypothesized that prescription of
antiretroviral therapy (ART) is an important intermediate factor
in racial/ethnic disparities in virological suppression, as captured
in the Figure 1 causal diagram. Furthermore, suppose that the
researcher is interested in the potential impact on the aforemen-
tioned disparity of intervening on ART prescription. Standard
stratification-based approaches to estimate the potential impact
would probably entail examining the racial/ethnic disparity after
controlling for ART prescription via restricting the analytical
sample to persons who have been prescribed ART or performing
that minimize selection bias without blocking pathways of inter-
est (16, 25–28). To aid our description, we use this framework to
analyze longitudinal data on 2,329 participants enrolled in the
CFAR [Centers for AIDS Research] Network of Integrated
Clinical Systems (CNICS).
CONCEPTUAL ANDMETHODOLOGICAL FRAMEWORK
Definition of the CDE and the PE
The total effect (TE) captures the effect of a given exposure
on an outcome that operates through all intermediate pathways.
The CDE represents the effect that the exposure has on the out-
come if everyone in a given population were uniformly assigned
to have a specific level for the mediator of interest or the dis-
tribution of the mediator of interest were intervened upon
(16, 21, 24, 29). The TE and CDE can be used to estimate the
proportion eliminated (PE) (i.e., the proportion of the TE that
could be eliminated through the aforementioned uniform
assignment) (24).
The CDE and PE are particularly useful for evaluating the
potential population impact on HIV racial/ethnic disparities
of interventions, given that the CDE and PE quantify the
impact of interventions targeted at the intermediate factor
rather than solely the exposure. Such interventions are necessary
in this context because the intermediates thatmost likely contrib-
ute to HIV racial/ethnic disparities tend to be more amenable to
intervention than race/ethnicity (5, 6, 11, 12, 30–37). Thus, the
CDE and PE provide quantities that capture the potential impact
of real-world policy interventions. Although it is not realistic
to assign the level or distribution of the intermediate to be the
same for the entire population, the PE obtained from such an
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Figure 1. Causal diagram depicting receipt of human immunodeficiency virus (HIV) medical care and use of antiretroviral therapy (ART) as the
mainmediators of the influence of race/ethnicity on HIV-related outcomes in adulthood. AIDS, acquired immunodeficiency syndrome.
standard regression adjustment for ART prescription (6, 11–14). 
However, as depicted in Figure 1, the aforementioned restriction 
or standard regression adjustment may overestimate or underesti-
mate the potential impact by introducing selection bias due to the 
presence of common causes (e.g., behavioral factors) of ART 
prescription and virological suppression that results in collider-
stratification bias when ART prescription is controlled for via 
restriction or standard regression adjustment (15–19).
Collider-stratification bias occurs via the path from race/
ethnicity to ART prescription to the common causes (e.g., behav-
ioral factors) to virological suppression (15–19). Based on the 
Figure 1 causal diagram, this collider-stratification bias can only 
be minimized via standard stratification-based approaches if all 
of the common causes of ART prescription and virological sup-
pression in Figure 1 are measured. However, even if all of the 
common causes have been measured, because several of the 
previously-referred-to common causes are influenced by race/
ethnicity, the impact of intervening on ART prescription may 
still be overestimated. This overestimation may occur because 
controlling for common causes that are influenced by race/ethnic-
ity via restriction or standard regression adjustment blocks the 
effect that race/ethnicity has on virological suppression through 
the common causes determined by race/ethnicity but not operating 
through ART prescription (15–19). Further detail regarding how 
causal diagrams can be used to identify selection bias or blocked 
pathways is included in the appendix of Hernán et al. (20).
Informed by prior work (16, 21–24), here we describe a con-
ceptual and methodological framework for appropriately eval-
uating the potential population impact on HIV-related racial/
ethnic disparities in adulthood of intervening on specific targets.  
We reframe relevant scientific questions as a controlled direct 
effect (CDE) and apply more modern approaches for estimation
intervention can provide an upper bound regarding the impact
of the intervention. However, approaches within the framework
can be pursued if more than an upper bound is preferred (25).
We focus on estimating the upper bound via assigning every-
one to have the same level of the intermediate.
Even if a potential intermediate turns out not to mediate HIV
racial/ethnic disparities because race/ethnicity does not influence
the potential intermediate, if there is an interaction between race/
ethnicity and the potential intermediate in their impact on the
outcome, interventions targeted at the potential intermediate can
still affect HIV racial/ethnic disparities as quantified by the CDE
and PE (24). Therefore, we refer to the nonexposure variable
under consideration for intervention as a potential intermediate/
mediator rather than an intermediate/mediator to allow for the
evaluation of interventions focused on mediators as well as
hypothesized mediators that do not mediate the disparity but
still affect the outcome.
Estimation of the CDE and the PE
VanderWeele (16) outlined methods for estimating the CDE
while accounting for potential interactions between the expo-
sure and the potential intermediate using the g-method, inverse
probability weighted marginal structural models. Formulas for
calculating the PE when the measure of effect was a difference
in themean outcome (e.g., risk difference) or another function
(e.g., risk ratio) were later provided (16, 23, 38). Highlighted in
this prior work (23) was the fact that despite being referred to as
a “proportion,” the PE will not necessarily fall between 0 and 1
when an interaction between the exposure and a potential inter-
mediate is present.
VanderWeele (16) also emphasized that standard stratification-
based approaches (e.g., standard regression adjustment) should
not be used to estimate the CDE and PE in settings that are the
focus of this paper due to the likely presence of a common cause
of the potential mediator and outcome that is influenced by the
exposure, as in Figure 1 (e.g., behavioral factors). As previously
described, the presence of the aforementioned common cause can
result in selection bias that cannot be minimized via standard
stratification-based approaches without potentially blocking path-
ways of interest. The aforementioned common causemay also be
related to selection (e.g., censoring), as illustrated in the later
CNICS example, which further limits the utility of standard
stratification-based approaches in this setting because standard
approaches cannot be used to minimize bias stemming from the
selectionmechanismwithout potentially also blocking pathways
of interest (18, 39). However, more modern techniques (e.g.,
inverse probability-of-censoring-and-potential-mediatorweighted
marginal structural models) can still be used for appropriate esti-
mation and have been previously summarized (18, 25, 39, 40).
Moreover, even if the data do not provide evidence of a sta-
tistically significant association between race/ethnicity and the
potential mediator, we caution against assuming the absence of
mediation and using standard stratification-based approaches
given the prior evidence.We caution because the lack of a statis-
tically significant association between race/ethnicity and the
potential mediator may be due to a lack of adequate power to
detect a statistically significant association rather than the
absence of mediation because race/ethnicity does not influence
the potentialmediator. Instead,we recommend that the conceptual
model be used to determine whether more modern approaches
are necessary and then use the relationships observed in the data
to aid in explaining the estimated CDE and PE.
Conditions sufficient for estimationof theCDE and thePE
The CDE and PE can be appropriately estimated when 1) the
assumptions of exchangeability and positivity hold for the expo-
sure, the potential intermediate, and the selection mechanism that
generated the analytical sample; 2) all fitted regression models
have been correctly specified; 3)measurement error is absent; and
4) the exposure, potential intermediate, and selection mechanism
are well-defined (15, 16, 41). To achieve exchangeability, there
must be no unmeasured confounding of the exposure-outcome
relationship or the potential mediator-outcome relationship. Fur-
thermore, there must be no unmeasured sources of selection bias.
To achieve positivity, there must be a nonzero probability of each
level of the exposure within every observed combination of the
confounders. Similarly, there must be a nonzero probability of
each level of the potential intermediate within every observed
combination of the relevant confounders and the exposure. There
must also be a nonzero probability of being selected within every
observed combination of relevant determinants of selection,
including the exposure and potential intermediate.
Correct model specification means that the model choice,
including functional forms, is correct in all fitted regression
models. Well-defined exposures, potential intermediates, and
selection mechanisms do not suffer from interference (42) and
correspond to a single well-defined intervention or have ver-
sion irrelevance when more than one well-defined intervention
exists (43). Given that race/ethnicity is not a well-defined expo-
sure because it does not correspond to a well-defined inter-
vention and is less amenable to intervention, race/ethnicity does
not represent a point of intervention in the framework. How-
ever, because the traditional definitions of the TE, CDE, and
PE imply an intervention on the exposure and potential inter-
mediate, we refrain from referring to the aforementioned quan-
tities as the TE, CDE, and PE in the framework. Instead, and
consistent with prior work (21, 22), in the framework we refer
to the TE as the racial/ethnic disparity that exists before an
intervention on the potential intermediate; to the CDE as the
racial/ethnic disparity that exists after an intervention on the poten-
tial intermediate; and to the PE as the proportion of the racial/
ethnic disparity that is eliminated due to an intervention on the
potential intermediate.
Conceptual model
Next we present a conceptual model for evaluating interven-
tions upon potential intermediates on racial/ethnic disparities
in outcomes (e.g., virological suppression) among HIV-infected
adults. Such a conceptual model is necessary to appropriately
evaluate interventions. Themodel we offer can be easilymodified
to explore other endpoints (e.g., HIV infection). Figure 1 is a
causal diagram that presents a conceptual model for the influ-
ence of race/ethnicity on outcomes among HIV-infected adults,
where receipt of HIVmedical care and ART use (i.e., prescrip-
tion, modification, and adherence) are the main potential media-
tors of racial/ethnic disparities in outcomes among HIV-infected
adults (5, 6, 11, 12, 30–36).
we modified the data to correspond to an interval cohort (61),
where all clinical and PROs data are collected and updated once
every 6 months subsequent to the first PROs assessment in the
study period.
Simple methods (e.g., last observation carried forward) were
used to complete clinical and PROs data that were unavailable.
Completed values were assumed to represent the truth. However,
beyond this demonstration, other, more sophisticated approaches
for addressing missing data should be considered, potentially in
sensitivity analyses (59, 62).
Race was a time-fixed binary indicator of AA race. The poten-
tial mediator was a time-updated binary indicator of meeting con-
ditions A and B below or meeting conditions A and C below.
Condition A was earliest ART prescription occurring before a
given PROs assessment. Condition B was ≥95% ART adher-
ence during the time between the earliest ART prescription and
the first subsequent PROs assessment. Condition C was ≥95%
ART adherence during the 6 months prior to a given PROs
assessment subsequent to the first ART prescription and the
earliest PROs assessment.
The outcome was a repeated binary indicator of achieving
virological suppression (i.e., ≤200 copies/mL) at the first HIV-
1 RNA assessment in the 6 months after the PROs assessment.
Birth year, gender, CD4 cell count, mental illnesses, HIV-1 RNA,
at-risk alcohol and drug use, and ART prescription and adher-
ence were covariates. Patients were followed until their death (if
applicable), July 30, 2014, or 1 year after their last PROs assess-
ment (i.e., dropout), whichever occurred first.
Conceptual model, notation, and statistical analysis
Figure 2 depicts the specific conceptual model that guided
the subsequently detailed notation and employed statistical
analysis based on the data available in CNICS. Regarding
notation, capital letters represent random variables, while low-
ercase letters or numbers represent particular values of random
variables. In the CNICS cohort of = …i 1, 2, , 2,329 AA and
Caucasian individuals, for patient i, let =X 0,1i correspond to
a binary indicator of AA race. Next, ( ) =M t 0,1i is a binary
indicator of meeting above-described conditions A and B or
above-described conditions A and C at a PROs assessment at
time t. Additionally, ( + ) =Y t 1 0,1i is a binary indicator of
achieving virological suppression at time t + 1 that was observed.
Next, L1,i is a vector denoting the levels of the measured co-
variates at or during the year prior to the first attended HIV
primary-care appointment during the study period, excluding
gender and year of birth; L2,i (t) is a vector denoting the levels
of the measured covariates at or during the year prior to time t,
excluding gender and year of birth; and Zi is a vector denoting
the levels of gender and year of birth. Furthermore, ( ) =C t 0,1i
is a binary indicator of being censored due to dropout or
death at time t. Lastly, = …t 0, 1, , 13 is time (in 6-month
periods) since the first PROs assessment, while a bar over a
random variable represents the history of that variable from
the first PROs assessment through time t. Therefore,
( + ) =¯ ( )Y t 1 0,1im t is a binary indicator of achieving virologi-
cal suppression at time t + 1 had patient i’s ART prescription
and adherence history at time t been set to ¯ ( )m t , possibly
contrary to fact. The subscript iwill henceforth be suppressed
wherever possible.
In Figure 1 as well as in the framework, race is considered to 
be a socially constructed classification based on phenotype that 
measures a combination of factors, including genes, socioeco-
nomic position, heritage, culture, and historical factors such as 
structural racism and discrimination prior to or at birth (21, 22, 
44). Race/ethnicity may influence the likelihood of receipt of 
HIV medical care, ART use, and HIV-related outcomes in adult-
hood through several pathways, including behavioral, biologi-
cal, psychological, and social pathways, as well as economic 
factors in childhood and adulthood (45–56). In prior work 
(21, 22), some of the above-mentioned factors present prior 
to or at birth have been considered to be confounders of the 
relationship between race/ethnicity and a given outcome of 
interest. However, because 1) researchers will often not have 
the data required to differentiate among the components of the 
framework’s definition of race/ethnicity and 2) race/ethnicity 
is not a point of intervention, for simplification we have included 
confounding factors in the framework’s definition of race/
ethnicity. But, as in prior work (21, 22, 44), if relevant data are 
available, the framework can be modified to examine certain as-
pects of race/ethnicity (e.g., culture). Such relevant data include 
data on components not of interest that the investigator considers 
to be potential confounders.
APPLICATION
Research question
A policy-relevant research question that could be answered 
using the framework is, “Would racial disparities in HIV virologi-
cal suppression in adulthood remain between AAs and Cauca-
sians had both groups been universally prescribed ART and were
≥95% adherent to their prescribed ART regimens after entering 
HIV care?”
Study population, design, and measures
We used the framework to analyze modified data on adult 
HIV-infected patients enrolled in 7 US HIV  clinics in CNICS.  
Data modifications are briefly described below. The secondary 
data analysis presented below was approved by the institutional 
review boards at Brown University and the 7 clinic sites. Addi-
tional details concerning CNICS are provided elsewhere (57).
CNICS collects relevant information from medical records 
and through clinical assessments of patient reported data 
or outcomes (PROs) (58) captured every 4–6 months.  We  
used data from 2,329 male and female AA and Caucasian adults 
who had necessary data available (e.g., attendance at 1 or more 
HIV primary-care appointments during the study period (Janu-
ary 1, 2008–July 30, 2014)) and were ART prescription-naive 
at the start of the study period. We assumed that any potential 
selection bias due to restricting the sample to patients with the 
necessary data available was negligible, to focus on minimiz-
ing potential sources of selection bias induced when trying to 
estimate the racial disparity in virological suppression after inter-
vening on ART prescription and adherence in the analytical sam-
ple. However, beyond this demonstration, the potential sources 
of selection bias that we assumed to be negligible should be 
more thoroughly considered, potentially in sensitivity analyses 
(15, 21, 59). To avoid selection bias due to pattern of care (60),
The racial disparity in virological suppression that exists prior to intervening on ART was estimated on the risk difference scale
fromα2 in the followingmodified Poisson regressionmodel (63):
[ ( + ) | ] = α + α ( ) + α + α ( )E Y t X Z f t X Z1 , , Model 10 1 2 3
where (⋅)f is a function of time. Model 1 was fitted using participant-specific inverse probability-of-censoring weights estimated
from the following equation:
∏( ) = [ ( + ) = |
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Inverse probability-of-censoring weights were used to minimize the potential for selection bias because of censoring due to
dropout or death related to certain measured covariates. For comparison, an unadjusted version of model 1 was also fitted based
on the unweighted data that solely included time and race as independent variables. An adjusted version of model 1 was also fit-
ted based on the unweighted data that included time and race as well as all of the measured covariates that were used to predict
censoring in equation 1 (excluding ART prescription and adherence) as independent variables.
The racial disparity that would have existed had all AAs and Caucasians been prescribed ART and been ≥95% ART-adherent
during the prior 6 months or the period between the first ART prescription and the earliest PROs assessment was estimated from
β + β2 4 in the followingmodified Poisson regression model (63):
[ ( + ) | ] = β + β ( ) + β + β ( ) + β × ( ) + β ( )¯ ( )E Y t X Z f t X m t X m t Z1 , . Model 2m t 0 1 2 3 4 5
For simplicity, model 2 assumed that virological suppression depended only on ART prescription and adherence reported at
the most recent prior PROs assessment, but other specifications are possible (60). Model 2 was fitted using participant-
specific inverse probability-of-censoring-and-potential-mediator weights estimated from the product of equation 1 and
equation 2,
∏( ) = [ ( ) = |
¯ ( − ) ¯ ( ) = ]
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Figure 2. Causal diagram depicting the relationship between African-American race and virological suppression in the unweighted data among
2,329 human immunodeficiency virus–infected African-American and Caucasian adults, CFAR Network of Integrated Clinical Systems, 2008–2014.
Unmeasured variables have been omitted for simplicity. A box appears around “Censored” because the analysis is restricted to those participants
who remain not censored due to dropout or death. ART, antiretroviral therapy.
race, the potential mediator, and all of the measured covariates
that were used to predict censoring or ART prescription and
adherence in equations 1 and 2 as independent variables.
The proportion of the racial disparity that was eliminated on the
risk difference scalewas estimated based on equation 3,
α − (β + β )
α






























Figure 3. Causal diagrams depicting the relationship between African-American (AA) race and virological suppression in the weighted data
among 2,329 human immunodeficiency virus (HIV)–infected AA and Caucasian adults, CFAR Network of Integrated Clinical Systems, 2008–
2014. In diagram A, potential selection bias because of censoring due to dropout or death related to certain measured covariates is accounted for.
In diagram B, potential selection bias because of censoring due to dropout or death and potential confounding of the relationship between antiretro-
viral therapy (ART) prescription and adherence and virological suppression related to certain measured covariates is accounted for. Unmeasured
variables have been omitted for simplicity. A box appears around “Censored” because the analysis is restricted to those participants who remain
not censored due to dropout or death. The arrows from gender, year of birth, and AA race to “Censored” and “ART prescription and adherence”
remain because gender, year of birth, and AA race were used to stabilize the weights.
Inverse probability-of-censoring-and-potential-mediator 
weights were used to minimize the potential for selection bias 
because of censoring due to dropout or death related to certain 
measured covariates, as well as to control for confounding of 
the potential mediator-outcome relationship. For comparison, 
an unadjusted version of model 2 was also fitted using the 
unweighted data that solely included time, race, and the potential 
mediator as independent variables. An adjusted version of model 
2 was also fitted based on the unweighted data that included time,
or an equivalent equation derived from the unadjusted or
adjusted analysis. Other representations of the aforementioned
proportionmay be considered (38). To aid in explainingwhether
the equation 3 estimate was due to mediation, interaction, both,
or neither, an additional modified Poisson regression model,
model 3, was fitted using the equation 1 weights with ART pre-
scription and adherence as a repeated outcome and time, birth
year, race, and gender as predictors.
Logistic regression models were used to estimate weights.
In all modified Poisson and logistic regression models, linear
and quadratic terms were used to fit continuous predictors,
while indicators were used to fit categorical predictors. Gener-
alized estimating equations (64, 65) were used to fit all modi-
fied Poisson regression models. Analyses were performed in
SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina). The
SAS code used to perform analyses is included in the Web
Appendix (available at https://academic.oup.com/aje).
RESULTS
The weights that were estimated to fit models 1–3 had mean
values of 1.04 (standard deviation (SD), 0.42) and 1.05 (SD,
0.70) with ranges of 0.11–7.15 and 0.02–27.34, respectively.
Thus, the weights estimated for models 1 and 3 were well-
behaved and used to fit models 1 and 3. However, the weights
estimated for model 2 were extreme (e.g., 1/0.02 = 50) and indi-
cated potential nonpositivity or model misspecification (66).
Therefore, the weights estimated for model 2 were truncated
at the first and 99th percentiles (66, 67) prior to using them to
fit model 2. The aforementioned truncation yielded amean value
of 1.03 (SD, 0.47) with a range of 0.09–3.48.
Assuming that all sufficient conditions hold, parts A and B of
Figure 3 depict the weighted populations used to fit models
1 and 2, respectively. Table 1 provides the racial disparities
derived frommodels 1 and 2 or their equivalent unadjusted and
adjusted versions. Compared with Caucasians, the weighted risk
difference for achieving virological suppression for AAs was
−0.09 (95% confidence interval (CI): −0.12, −0.05). After uni-
versal prescription of and ≥95% adherence to ART, the afore-
mentioned risk difference was reduced by 38% (95% CI: −25,
89), thus indicating that universal ART prescription and adher-
ence after entering HIV care could considerably reduce racial
disparities in virological suppression in adulthood. However, the
confidence interval for the aforementioned reduction was impre-
cise. Furthermore, the estimated values for β3 and β4 (i.e., 0.20
(95% CI: 0.17, 0.22) and 0.05 (95% CI: −0.01, 0.10), respec-
tively) in model 2, along with the point estimate (i.e., 0.02, 95%
CI: 0.00, 0.04) for race in model 3, indicate that the aforemen-
tioned 38% reduction may be due to mediation and interaction
because of the nonnull (i.e., nonzero) estimated values for β3 and
β4 and the race point estimate in model 3. The corresponding
reduction in the risk difference in the adjusted analysis was
smaller (i.e., 33%, 95% CI: −53, 104) than the estimated
reduction based on the weighted approach.
DISCUSSION
Comparedwith standard approaches, the framework described
here provides potentially more accurate techniques for using
observational data to evaluate the potential population impact
on HIV racial/ethnic disparities in adulthood of intervening
upon specific targets. The gain in accuracy is due to better min-
imizing the potential for selection bias while avoiding path-
ways of interest from being blocked. For the CNICS example,
the proportion of the racial disparity that was eliminated based
on the standard regression approach quantitatively differed from
the corresponding proportion estimated based on the inverse
probability weighted analysis. This difference may have been
due to the described framework better minimizing the potential
for selection bias and not blocking pathways of interest. How-
ever, the above-mentioned difference was small, and the confi-
dence intervals for the proportions estimated from the adjusted
Table 1. Racial Disparity (African Americans vs. Caucasians) in Virological Suppression Among 2,329 Adult Male and
Female Participants in the CFARNetwork of IntegratedClinical Systems, 2008–2014
Racial Disparity RiskDifference 95%CI
Proportion of
Disparity Eliminateda 95%CI
Unadjusted racial disparity −0.10 −0.14,−0.07
Adjustedb racial disparity −0.06 −0.09,−0.02
Weightedc racial disparity −0.09 −0.12,−0.05
Unadjusted racial disparity given universal
prescription of and≥95% adherence to ART
−0.05 −0.08,−0.02 0.52 0.19, 0.81
Adjustedb racial disparity given universal
prescription of and≥95% adherence to ART
−0.04 −0.08, 0.00 0.33 −0.53, 1.04
Weightedc racial disparity given universal
prescription of and≥95% adherence to ART
−0.05 −0.10,−0.01 0.38 −0.25, 0.89
Abbreviations: ART, antiretroviral therapy; CI, confidence interval.
a Difference between the proportion eliminated presented in the table and the proportion eliminated calculated on the
basis of risk differences included in the table due to rounding.
b Accounts for year of birth, gender, CD4 cell count, HIV-1 RNA level, mental illness, and at-risk alcohol and drug use as
covariates.
c Accounts for year of birth, gender, CD4 cell count, HIV-1 RNA level, mental illness, at-risk alcohol and drug use, and
ART use as covariates.
and inverse probability weighted analyses were both imprecise
and included a value of 0.
Regardless, employing the framework may lead to new in-
ferences or the refinement of prior inferences (12, 13) based on
standard approaches regarding the potential impact on HIV
racial/ethnic disparities in adulthood of intervening upon spe-
cific targets. Employing the framework may also provide evi-
dence regarding whether an observed impact is likely to be due
to interaction, mediation, or both. Although evidence regarding
whether a reduction in a racial/ethnic disparity is due to inter-
action, mediation, or both may not have policy implications,
because a considerable reduction may warrant an intervention
regardless of the source, learning whether an observed reduc-
tion is due to interaction,mediation, or bothwill probably enhance
the conceptual models that are used to explain and identify the
best targets to reduce racial/ethnic disparities. Enhanced con-
ceptual models will help ensure that the most appropriate
methodological approaches are used in future analyses when
studying racial/ethnic disparities. Note that to accurately quan-
tify how much of a reduction is due to interaction, mediation,
or both, other techniques than those used to analyze the CNICS
data are needed (68).
In closing, we encourage researchers studying HIV and non-
HIV racial/ethnic disparities, as well as other health disparities
with a causal structure similar to the structure included in Figure 1
and an exposure that is difficult to intervene on (e.g., socioeco-
nomic position), to readily adapt and apply the framework.
Because factors relevant to studying health disparities may
often not be measured (69), as in the CNICS example, con-
ditions sufficient for accurate estimation (e.g., exchangeability)
may frequently not hold. Thus, beyond our simplified demon-
stration, which focused on illustrating how to apply the frame-
work using the CNICS data in as straightforward a manner as
possible, when feasible the framework should be applied in
combination with sensitivity analyses (59, 62, 70) when suffi-
cient conditions probably do not hold.
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